Palisade Bio, Inc. (PALI) Stock Forecast
PALI analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.70 / 5 from 10 analysts
- Price target
- $9.80 average of analyst targets
- Upside to target
- +595.0% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.06
- 52-week range
- $1.35 – $2.80
PALI analyst ratings
10 analystsNumber of analysts at each rating.
PALI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PALI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.07 | −$0.05 | −$0.38 | +83.9% | 8 |
| Current fiscal year (2026) | −$0.22 | −$0.25 | −$0.20 | −$0.30 | +25.4% | 8 |
| Next fiscal year (2027) | −$0.28 | −$0.40 | −$0.20 | −$0.22 | −26.8% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PALI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $437,500 | $0 | $1.0M | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 8 |
PALI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PALI revenue: reported and forecast
PALI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −0.2% | 1 up · 5 down |
| Current fiscal year (2026) | −$0.24 | −$0.23 | −$0.23 | −$0.23 | −$0.22 | −6.2% | 2 up · 5 down |
| Next fiscal year (2027) | −$0.29 | −$0.28 | −$0.28 | −$0.28 | −$0.28 | −0.7% | 1 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PALI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PALI beat in 4 of 12.
What analysts expect from PALI
10 analysts cover Palisade Bio; their consensus rating is strong buy (4.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.80, 595.0% above the latest close of $1.41. Analysts expect earnings of −$0.22 per share for 2026, +25.4% from a year earlier. For 2027 the average estimate is −$0.28 per share. Palisade Bio beat the EPS estimate in 4 of the last 12 quarters.
Related: PALI income statement, PALI key metrics, PALI chart. See the PALI stock overview for the latest quote and news.
PALI forecast FAQ
What is Palisade Bio's price target?
The average analyst price target for Palisade Bio is $9.80, 595.0% above the latest close of $1.41.
Is Palisade Bio a buy, hold or sell?
Of 10 analysts covering Palisade Bio, 7 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Palisade Bio's EPS forecast?
Analysts forecast −$0.22 per share for 2026 (range −$0.25 to −$0.20); for 2027 the estimate is −$0.28.
What is Palisade Bio's revenue forecast?
The average revenue estimate for 2026 is $0.4 million, growth of 0.0%.
When does Palisade Bio report earnings?
Palisade Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.06.
Does Palisade Bio usually beat earnings estimates?
Palisade Bio reported EPS at or above the analyst estimate in 4 of the last 12 quarters.